5-HT2a Receptor RNAi Program
Neuropsychiatric disorders (e.g., anxiety, memory impairment)
Key Facts
About Cognigenics
Cognigenics is an early-stage biotech pioneering intranasal RNAi delivery for precision neuropsychiatry. Founded in 2020 and based in San Diego, the company's core technology, iRNAi™, is a non-invasive platform intended to silence specific genes in key brain circuits to address the root causes of disorders related to memory and mood. While still in pre-clinical development, the platform represents a potentially disruptive modality for central nervous system (CNS) therapeutics, targeting a significant unmet medical need with a mechanism that promises precision and durability. The company appears to be privately held and pre-revenue, advancing its research through scientific publication and accelerator participation.
View full company profile